ANIP
Price
$69.01
Change
-$0.08 (-0.12%)
Updated
Aug 7 closing price
Capitalization
1.43B
Earnings call today
ESPR
Price
$1.81
Change
-$0.11 (-5.73%)
Updated
Aug 7 closing price
Capitalization
495.94M
89 days until earnings call
Interact to see
Advertisement

ANIP vs ESPR

Header iconANIP vs ESPR Comparison
Open Charts ANIP vs ESPRBanner chart's image
ANI Pharmaceuticals
Price$69.01
Change-$0.08 (-0.12%)
Volume$780.57K
Capitalization1.43B
Esperion Therapeutics
Price$1.81
Change-$0.11 (-5.73%)
Volume$5.23M
Capitalization495.94M
ANIP vs ESPR Comparison Chart in %
Loading...
ANIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANIP vs. ESPR commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and ESPR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (ANIP: $69.01 vs. ESPR: $1.81)
Brand notoriety: ANIP and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ANIP: 249% vs. ESPR: 121%
Market capitalization -- ANIP: $1.43B vs. ESPR: $495.94M
ANIP [@Pharmaceuticals: Other] is valued at $1.43B. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIP’s FA Score shows that 0 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • ANIP’s FA Score: 0 green, 5 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, both ANIP and ESPR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIP’s TA Score shows that 5 TA indicator(s) are bullish while ESPR’s TA Score has 4 bullish TA indicator(s).

  • ANIP’s TA Score: 5 bullish, 3 bearish.
  • ESPR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ANIP is a better buy in the short-term than ESPR.

Price Growth

ANIP (@Pharmaceuticals: Other) experienced а +8.93% price change this week, while ESPR (@Pharmaceuticals: Other) price change was +27.46% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.12%. For the same industry, the average monthly price growth was +73.14%, and the average quarterly price growth was +82.67%.

Reported Earning Dates

ANIP is expected to report earnings on Aug 08, 2025.

ESPR is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+3.12% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIP($1.43B) has a higher market cap than ESPR($496M). ANIP YTD gains are higher at: 24.837 vs. ESPR (-17.727). ANIP has higher annual earnings (EBITDA): 107M vs. ESPR (-150.11M). ANIP has more cash in the bank: 221M vs. ESPR (82.2M). ESPR has less debt than ANIP: ESPR (266M) vs ANIP (286M). ANIP has higher revenues than ESPR: ANIP (487M) vs ESPR (116M).
ANIPESPRANIP / ESPR
Capitalization1.43B496M288%
EBITDA107M-150.11M-71%
Gain YTD24.837-17.727-140%
P/E Ratio79.85N/A-
Revenue487M116M420%
Total Cash221M82.2M269%
Total Debt286M266M108%
FUNDAMENTALS RATINGS
ANIP vs ESPR: Fundamental Ratings
ANIP
ESPR
OUTLOOK RATING
1..100
7423
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
36100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
5036
P/E GROWTH RATING
1..100
93100
SEASONALITY SCORE
1..100
2150

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for ANIP (91) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew somewhat faster than ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for ESPR (100) in the Biotechnology industry. This means that ANIP’s stock grew somewhat faster than ESPR’s over the last 12 months.

ANIP's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ANIP’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (36) in the Biotechnology industry is in the same range as ANIP (50) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to ANIP’s over the last 12 months.

ANIP's P/E Growth Rating (93) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ANIP’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIPESPR
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
69%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ANIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADCIX24.96N/A
N/A
American Century Disciplined Growth I
AMIDX13.89N/A
N/A
Amana Developing World Institutional
RSMVX10.49N/A
N/A
William Blair Small-Mid Cap Value R6
TRMVX27.04N/A
N/A
SEI Large Cap Value F (SIMT)
RBAIX28.31N/A
N/A
T. Rowe Price Balanced I

ANIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIP has been loosely correlated with ORGO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIP jumps, then ORGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIP
1D Price
Change %
ANIP100%
-0.12%
ORGO - ANIP
50%
Loosely correlated
+0.44%
DRRX - ANIP
38%
Loosely correlated
+1.62%
PRGO - ANIP
34%
Loosely correlated
-3.30%
EBS - ANIP
33%
Poorly correlated
+36.65%
ESPR - ANIP
32%
Poorly correlated
-5.73%
More

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and DVAX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and DVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-5.73%
DVAX - ESPR
33%
Poorly correlated
-1.16%
ALKS - ESPR
31%
Poorly correlated
+0.19%
AQST - ESPR
30%
Poorly correlated
-1.50%
AMRX - ESPR
28%
Poorly correlated
+1.99%
AMPH - ESPR
27%
Poorly correlated
+3.84%
More